A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane
NCT00097487 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2018-03-02
Summary
This study is a Phase IV, prospective, nonrandomized, community-based study of clinical outcomes in patients with metastatic breast cancer treated with Herceptin and a taxane.
Conditions
Sponsors & Collaborators
-
Genentech, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-11-30
- Completion
- 2004-09-30
More Related Trials
-
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
NCT00033514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu
NCT00153218 ·Status: COMPLETED
-
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2
NCT00019812 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
NCT00191451 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
NCT01276041 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
NCT00191373 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
NCT00059852 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
NCT00885755 ·Status: COMPLETED ·Phase: PHASE2
-
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
NCT00386685 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
NCT01480674 ·Status: COMPLETED
-
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
NCT00387907 ·Status: COMPLETED ·Phase: PHASE2
-
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
NCT04609540 ·Status: UNKNOWN
-
Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
NCT03876587 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
NCT01912963 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
NCT00095706 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
NCT01989676 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
NCT04742153 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
NCT00036868 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
NCT02139358 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
NCT01097460 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
NCT00807859 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
NCT05141708 ·Status: COMPLETED
-
Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
NCT00440622 ·Status: TERMINATED ·Phase: PHASE3
-
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
NCT00193063 ·Status: COMPLETED ·Phase: PHASE2